雄激素受体在乳腺癌分子亚型中的表达及其与临床病理特征的关系  

Androgen receptor expression in molecular subtypes of breast cancer and its relationship with the clinicopathological features

作　　者：吴兴龙[1] 杨华[1] 曾丽莉[1] 杨永福[1] 王玲[1] 刘华庆[1] 

机构地区：[1]遵义医学院附属医院病理科,遵义563000

出　　处：《临床与实验病理学杂志》2015年第9期976-980,共5页Chinese Journal of Clinical and Experimental Pathology

基　　金：遵义医学院中青年启动基金[院字(2010)01号20120426]

摘　　要：目的探讨雄激素受体(androgen receptor,AR)在乳腺癌不同分子亚型中的表达及其与临床病理特征的关系。方法采用免疫组化En Vision两步法检测153例乳腺癌组织中雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、HER-2、CK5/6、CK14表达,并依据免疫表型划分为Luminal A型、Luminal B型、HER-2过表达型、Basal-like型和Normal-like型5个分子亚型,其分别为84、27、14、11和17例。对比分析AR在5个分子亚型中的分布及其与发病年龄、病理组织学分级、肿瘤大小、淋巴结状态及临床分期等的相关性。结果 153例乳腺癌组织中AR的阳性率为73.20%,在5个分子亚型中以Luminal A型为主(62.50%)。在HER-2阴性与阳性乳腺癌中,AR的阳性率分别为75.00%和68.29%,两者间的表达差异无统计学意义(P=0.196)。在153例乳腺癌中有23例(15.03%)三阴型乳腺癌(ER、PR和HER-2均阴性),有15例(9.80%)乳腺癌ER、PR、AR均阴性,有8例(5.23%)四阴型乳腺癌(ER、PR、AR和HER-2均阴性)。AR在ER/PR阳性与阴性乳腺癌之间的表达差异有统计学意义(P=0.001),与ER/PR表达呈正相关( r_s=0.874,P=0.024)。AR在组织学分级之间的表达差异有统计学意义(P=0.022),与组织学分级呈负相关( r_s=-0.201,P=0.013)。AR阳性与肿瘤大小有关,与淋巴结转移(P=0.211)及临床分期无关(P=0.065)。结论 AR在乳腺癌组织中的表达及其与临床病理特征的关系为进一步改善乳腺癌的分子分型提供依据,也为临床治疗及判断预后提供理论基础。Purpose To investigate the expression of androgen receptor （ AR） in molecular subtypes of breast cancer and its relation-ship with clinicopathological features. Methods The expression of estrogen receptor （ER）, progesterone receptor （PR）, HER-2, CK5/6, CK14 in breast cancer was detected by EnVision immunohistochemical staining, and they further be divided into 84 Luminal A subtypes, 27 Luminal B subtypes, 14 HER-2 overexpression subtypes, 11 Basal-like subtypes, and 17 Normal-like subtypes, respec-tively. The distribution of AR in 5 molecular subtypes and its relationship with clinicopathological factors, such as age, histopathologi-cal grading, tumor size, lymph node status and clinical staging, were analyzed. Results In 153 cases of breast cancer, the positive rates of AR expression were 73. 20%, Luminal A was the majority （ 62. 50%） in 5 molecular subtypes. In the HER-2 negative and positive breast cancer, the positive rates of AR expression were 75. 00% and 68. 29% and the difference between the two groups was no statistical significant （P=0. 196）. Of the 153 breast cancers, 23 （15. 03%） were triple-negative breast cancers （ER-, PR- and HER-2-）, 15 （9. 80%） breast cancers were negative for ER, PR and AR, 8（5. 23%） breast cancers were quadruple negative （ER-, PR-, AR- and HER-2 -） . There was significant difference of the expression of AR in ER/PR positive and negative breast cancer （P=0. 001）,it was positively correlated with ER/PR protein expression （rs =0. 874, P=0. 024）. The difference of AR ex-pression between histological grading was statistically significance （ P=0. 022 ） , the expression of AR was negatively correlated with histopathologic grading （rs = -0. 201, P=0. 013）. The positive expression of AR was related to tumor size, but not correlated with lymph node metastasis （ P=0. 211 ） and clinical staging （ P=0. 065 ） . Conclusion The expression of AR in breast cancer tissues and its relationship with clinicopathological features may pro

关 键 词：乳腺肿瘤 雄激素受体 分子分型 临床病理特征 

分 类 号：R735.2[医药卫生—肿瘤]